Annual report pursuant to Section 13 and 15(d)

Document and Entity Information

Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Mar. 16, 2022
Jun. 30, 2021
Cover [Abstract]        
Entity Registrant Name Ra Medical Systems, Inc.      
Entity Central Index Key 0001716621      
Document Type 10-K/A      
Document Period End Date Dec. 31, 2021      
Amendment Flag true      
Entity Voluntary Filers No      
Entity Well Known Seasoned Issuer No      
Entity Current Reporting Status Yes      
Current Fiscal Year End Date --12-31      
Trading Symbol RMED      
Entity Filer Category Non-accelerated Filer      
Entity Common Stock, Shares Outstanding     31,458,547  
Entity Public Float       $ 24.1
Document Fiscal Year Focus 2021      
Document Fiscal Period Focus FY      
Entity Emerging Growth Company true      
Entity Small Business true      
Entity Shell Company false      
Entity Ex transition period false      
Title of 12(b) Security Common Stock, $0.0001 par value      
Security Exchange Name NYSEAMER      
Entity Tax Identification Number 38-3661826      
Entity Address, Address Line One 2070 Las Palmas Drive      
Entity File Number 001-38677      
Entity Address, City or Town Carlsbad      
Entity Address, State or Province CA      
Entity Address, Postal Zip Code 92011      
City Area Code 760      
Local Phone Number 804-1648      
Document Transition Report false      
Entity Incorporation, State or Country Code DE      
Entity Interactive Data Current Yes      
Document Annual Report true      
Auditor Name Haskell & White LP Deloitte & Touche LLP    
Auditor Firm ID 200 34    
Auditor Location Irvine, CA San Diego, CA    
ICFR Auditor Attestation Flag false      
Amendment Description Ra Medical Systems, Inc. (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Amended Form 10-K”), which was originally filed with the SEC on March 24, 2022, (the “Original Filing”) to amend Part IV, Item 15 - Exhibits and Financial Statement Schedules to correct an error in the Opinion to the Financial Statements of Deloitte & Touche LLP.  Part IV, Item 15 – Exhibits and Financial Statement Schedules has also been amended to include new consents of Deloitte & Touche LLP, Independent Registered Public Accounting Firm and Haskell & White LLP, Independent Registered Public Accounting Firm, and certifications from the Company’s Principal Executive and Principal Financial Officer as required by sections 302 and 906 of the Sarbanes Oxley Act of 2002. The consents are included in this Amended Form 10-K as Exhibits 23.2 and 23.1, respectively. The certifications are included in this Amended Form 10-K as Exhibits 31 and 32. This Amended Form 10-K does not modify, amend, or update in any way the financial statements set forth in the Original Filing and there have been no changes to the XBRL data filed in Exhibit 101 of the Original Filing. This Amended Form 10-K has not been updated for other events or information subsequent to the date of the filing of the Original Filing, except as noted above, and should be read in conjunction with the Original Filing and our other filings with the SEC.